January 16, 2018 08:24 AM EST

Eiger Bio scraps a mid-stage program after researchers record a clear flop in PAH, shares skid lower

John Carroll

Editor & Founder

Eiger BioPharmaceuticals $EIGR is scrapping one of its mid-stage programs for pulmonary arterial hypertension after their Phase II trial for ubenimex failed on several key …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eiger Bio scraps a mid-stage program after researchers record a clear flop in PAH, shares skid lower

John Carroll

Editor & Founder

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Eiger Bio scraps a mid-stage pro­gram af­ter re­searchers record a clear flop in PAH, shares skid low­er

John Carroll

Editor & Founder

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Eiger Bio scraps a mid-stage program after researchers record a clear flop in PAH, shares skid lower

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?